PRODUCT CATALOGUE A complete palette in Nuclear Medicine

Oncology

Cardiology

Neurology INTERNATIONAL CATALOGUE

This is a comprehensive list of all products. Some products may not be available in your country, depending upon registration status. IBA reserves the right to modify the availability date of the products contained herein. Please contact your local distributor for further information.

Approved SPC are available for download at: www.ibamolecular.eu

2 | IBA Molecular | Contents

PRODUCT INDEX

BY INDICATION ...... 6 BY NUCLIDE ...... 8

PRODUCT SPECIFICATIONS

PET ...... 11 Radiopharmaceuticals ...... 11

SPECT & THERAPY ...... 15 Radiopharmaceuticals ...... 15 Cold kits ...... 25 Generators ...... 35 Accessories ...... 39

RADIOCHEMICAL ...... 45

PACKAGING ...... 47

SERVICES ...... 51

GENERAL INFORMATION

COMMERCIAL INFORMATION ...... 54 SCIENTIFIC AND TECHNICAL INFORMATION ...... 55 UNITS ...... 57 DEFINITIONS ...... 58 NUCLIDE INDEX ...... 59 RADIOACTIVE DECAY TABLE ...... 61 LOCATIONS AND CONTACTS ...... 65

3 | IBA Molecular | INTERNATIONAL CATALOGUE

4 | IBA Molecular | Product index

By indication ...... 6 By nuclide ...... 8

Offering a comprehensive range in Nuclear Medicine

Fulfilling the needs of our customers can not be conceived in part only. Our product offering reflects our commitment to offer a complete radiopharmaceutical solution to nuclearists, from widespread to niche indications. With major applications in Oncology, Cardiology and Neurology, in PET, SPECT and Therapy, our range is one of the most comprehensive in the industry.

5 | IBA Molecular | INTERNATIONAL CATALOGUE

Products by indication

Brain Cardio-vascular system

DOPACIS® ANGIOCIS® SERALB-125 STAMICIS® TL-201-S-1 VASCULOCIS®

Thyroid Adrenal glands/Kidneys

CAPSION® NORCHOL-131 I-123-S-2 PENTACIS® I-131-S-1 RENOCIS® I-131-S-2 EDICIS™ 2 mg

Sentinel nodes Lymphatic system

® NANOCIS NANOCIS®

Lung Joints (various sizes)

PENTACIS® ERMM-1 PULMOCIS® RE-186-MM-1 VENTIBOX YMM-1 VENTICIS® II

Inflammation/ Liver infection

PHYTACIS® GA-67-MM-1 SCINTIMUN® 1 mg

Bones Others

CISNAF® ELUMATIC® III OSTEOCIS® (18F)-FDG TECEOS® MIBG-131-D QUADRAMET® MIBG-131-T TEKCIS™ YTRACIS® ZEVALIN®

6 | IBA Molecular | PET I-131-S-1 p 18 TECEOS ® p 33 Oral sodium iodide ( 131 I) for thyroid therapy. Kit for radiopharmaceutical preparation. Radiopharmaceuticals I-131-S-2 p 18 VASCULOCIS ® p 33 CISNAF ® p 12 131 Kit for radiopharmaceutical preparation. Sodium Fluoride ( 18 F) is used with positron Sodium iodide ( I) injection for thyroid emission tomography (PET) in bone imaging. diagnosis and therapy. ZEVALIN ® p 34 DOPACIS ® p 12 MIBG-131-T p 19 Radiopharmaceutical preparation for infusion (18 F) Fluorodopa is a solution used with Radiation therapy of tumour-tissue that is (labelleing with yttrium ( 90 Y)). positron emission tomography in neurology capable of retaining iobenguane. and oncology. Generators QUADRAMET ® p 20 FARNA FDG 3000 p 13 ® 153 ELUMATIC III p 36 Fludeoxyglucose ( 18 F) is indicated for use with Samarium ( Sm)-EDTMP for the relief of Technetium ( 99m Tc) generator 2-20GBq. positron emission tomography. bone pain in patients with multiple painful FDG-IBA P 13 osteoblastic skeletal metastases which take TEKCIS ™ p 37 Fludeoxyglucose ( 18 F) is indicated for use with up technetium ( 99m Tc)-labelled 2-50 GBq radionuclide generator. positron emission tomography in Oncology, bisphosphonates on bone scan. Cardiology, Neurology and Infectious. RE-186-MM-1 p 21 Accessories FLUORSCAN 3000 p 14 Rhenium ( 186 Re) sulphide for isotopic radiation Fludeoxyglucose ( 18 F) is indicated for use with ELUMATIC/TEKCIS synovectomy (medium size joints). positron emission tomography. ACCESSORIES YMM-1 p 23 CONT-ELU p 40 Yttrium ( 90 Y) citrate colloidal suspension for Lead shielding for elution vial. SPECT and Therapy isotopic radiation synovectomy (big size Radiopharmaceuticals joints). CONT-ELU-SP p 40 All lead glass shielding for elution vial. ® DIAGNOSIS YTRACIS p 23 Yttrium ( 90 Y) chloride radiopharmaceutical PROTEC-ELU p 40 GA-67-MM-17 p 17 precursor solution for the radiolabelling of Lead shielding for ELUMATIC III generator Gallium ( 67 Ga) citrate : supplied in parts. - non-specific tumor imaging and/or localizing carrier molecules. agent. OTHER - localization of inflammatory lesions. Kits for radiopharmaceutical VENTICIS ® II RADIOAEROSOL I-123-S-2 p 17 preparation Sodium iodide ( 123 I) for functional and DELIVERY SYSTEM p 41 ANGIOCIS ® p 26 morphological study of the thyroid gland. Radioaerosol delivery system for lung Kit for radiopharmaceutical preparation. MIBG-131-D p 19 investigation supplied in box of 5 circuits. ™ ® Iobenguane ( 131 I) for calculation of a EDICIS 2 mg p 26 Medical device, class IIa, in compliance with therapeutic iobenguane ( 131 I) dose from a Kit for radiopharmaceutical preparation. the Medical Devices Directive 93/42/EEC. prior tracer-dose. NANOCIS ® p 27 0459. NORCHOL-131 p 20 Kit for radiopharmaceutical preparation. VENTIBOX p 41 131 6 - iodomethylnorcholesterol ( I) for ® ® Lead shielded box for one VENTICIS II investigation of adrenocortical diseases. OSTEOCIS p 27 System. SERALB-125 p 21 Kit for radiopharmaceutical preparation. ® Iodinated ( 125 I) human serum albumin for PENTACIS ® p 28 CAPSION accessories p 42 determination of plasma and total blood Kit for radiopharmaceutical preparation. EDICIS ® accessories p 42 volume, and examination of albumin turnover. PHYTACIS ® p 28 SCINTIMUN ® accessories p 43 TL-201-S-1 p 22 Kit for radiopharmaceutical preparation. ® Thallium ( 201 Tl) chloride for myocardial STAMICIS accessories p 43 scintigraphy. PULMOCIS ® p 29 Kit for radiopharmaceutical preparation. THERAPY Radiochemical RENOCIS ® p 29 CAPSION ® p 16 Kit for radiopharmaceutical preparation. upon request Sodium iodide ( 131 I) capsules for thyroid therapy. SCINTIMUN ® 1 mg p 30 I-123-MPUP p 46 ERMM-1 p 16 Kit for radiopharmaceutical preparation. ® Erbium ( 169 Er) citrate for isotopic radiation STAMICIS p 31 synovectomy (small size joints). Kit for radiopharmaceutical preparation. Other possibilities upon request.

The availability of these products is dependant upon their registration status in each country. Please contact your local IBA Molecular representative for more information. Please refer to the Summary of Product Caracteristics available on www.iba-molecular.com for complete product information

7 | IBA Molecular | INTERNATIONAL CATALOGUE

Products by nuclide

Radiopharmaceuticals I-131-S-1 p 18 PHYTACIS ® p 28 Oral sodium iodide ( 131 I) for thyroid therapy. Kit for radiopharmaceutical preparation. 169 Er I-131-S-2 p 18 PULMOCIS ® p 29 ERMM-1 p 16 Sodium iodide ( 131 I) injection for thyroid Kit for radiopharmaceutical preparation. Erbium ( 169 Er) citrate for isotopic radiation diagnosis and therapy. RENOCIS ® p 29 synovectomy (small size joints). MIBG-131-D p 19 Kit for radiopharmaceutical preparation. 18 F Iobenguane ( 131 I) for calculation of a SCINTIMUN ® 1 mg p 30 131 Kit for radiopharmaceutical preparation. CISNAF ® p 12 therapeutic iobenguane ( I) dose from a Sodium Fluoride ( 18 F) is used with positron prior tracer-dose. STAMICIS ® p 31 emission tomography (PET) in bone imaging. MIBG-131-T p 19 Kit for radiopharmaceutical preparation. ® DOPACIS p 12 Radiation therapy of tumour-tissue that is TECEOS ® p 33 18 ( F) Fluorodopa is a solution used with capable of retaining iobenguane. Kit for radiopharmaceutical preparation. positron emission tomography in neurology TEKCIS™ p 37 and oncology. NORCHOL-131 p 20 131 2-50 GBq radionuclide generator FARNA FDG 3000 p 13 6-iodomethylnorcholesterol ( I) for ® Fludeoxyglucose ( 18 F) is indicated for use with investigation of adrenocortical diseases. VASCULOCIS p 33 positron emission tomography. Kit for radiopharmaceutical preparation. 186 FDG-IBA P 13 Re ZEVALIN ® p 34 18 Fludeoxyglucose ( F) is indicated for use with RE-186-MM-1 p 21 Radiopharmaceutical preparation for infusion positron emission tomography in Oncology, 90 Rhenium ( 186 Re) sulphide for isotopic radiation (labelling with Yttrium ( Y)) Cardiology, Neurology and Infectious. synovectomy (medium size joints). FLUORSCAN 3000 p 14 201 Tl Fludeoxyglucose ( 18 F) is indicated for use with 153 positron emission tomography. Sm TL-201-S-1 p 22 201 QUADRAMET ® p 20 Thallium ( Tl) chloride for myocardial 67 scintigraphy. Ga Samarium ( 153 Sm)-EDTMP for the relief of GA-67-MM-17 p 17 bone pain in patients with multiple painful 90 67 Y Gallium ( Ga) citrate: osteoblastic skeletal metastases which take - non-specific tumor imaging and/or localizing up technetium ( 99m Tc)-labelled YMM-1 p 23 agent. 90 bisphosphonates on bone scan. Yttrium ( Y) citrate colloidal suspension for - localization of inflammatory lesions. isotopic radiation synovectomy (big size

99m joints). 123 I Tc YTRACIS ® p 23 I-123-S-2 p 17 ANGIOCIS ® p 26 Yttrium ( 90 Y) chloride radiopharmaceutical Sodium iodide ( 123 I) for functional and Kit for radiopharmaceutical preparation. precursor solution for the radiolabelling of morphological study of the thyroid gland. ™ ® EDICIS 2 mg p 26 carrier molecules. Kit for radiopharmaceutical preparation. 125 I ELUMATIC ® III p 36 Radiochemical SERALB-125 p 21 Technetium ( 99m Tc) generator 2-20GBq. Iodinated ( 125 I) human serum albumin for 123 determination of plasma and total blood NANOCIS ® p 27 I p 46 volume, and examination of albumin turnover. Kit for radiopharmaceutical preparation. Upon request. OSTEOCIS ® p 27 131 I Kit for radiopharmaceutical preparation. CAPSION ® p 16 ® Sodium iodide ( 131 I) capsules for thyroid PENTACIS p 28 therapy. Kit for radiopharmaceutical preparation.

The availability of these products is dependant upon their registration status in each country. Please contact your local IBA Molecular representative for more information. Please refer to the Summary of Product Caracteristics available on www.iba-molecular.com for complete product information

8 | IBA Molecular | Product specifications PET

Radiopharmaceuticals ...... 11 SPECT & Therapy

Radiopharmaceuticals ...... 15 Cold kits ...... 25 Generators ...... 35 Accessories ...... 39 Radiochemical 45 Packaging 47 Services 51

9 | IBA Molecular | INTERNATIONAL CATALOGUE

10 | IBA Molecular | PET Radiopharmaceuticals

11 | IBA Molecular | INTERNATIONAL CATALOGUE

CISNAF ®

Fluorine-18 T1/2 = 109.8 min Sodium Fluoride ( 18 F) solution for injection

Availability Depending upon regions Please, contact your local IBA representative Ordering deadline Depending upon regions Please, contact your local IBA representative Radioactive concentrations 100 MBq/mL at the date and time of calibration Calibration 6 to 10 hours from the time of production Available quantities 50 to 1500 MBq per vial at calibration time Expiry 14 hours from the date of production Volume per vial 0.5 to 15 mL Radiochemical purity ≥ 98,5% pH and composition 5.0-8.5 ; Sodium fluoride ( 18 F), sodium chloride and water for injections Storage Store in the original packaging Indication Medicinal product for diagnostic use only. Indicated for use with positron emission tomography (PET) in bone imaging. Please, refer to the SPC.

DOPACIS ®

Fluorine-18 T1/2 = 109.8 min Fluorodopa ( 18 F) SOLUTION FOR INJECTION

Availability Depending upon regions Please, contact your local IBA representative Ordering deadline Depending upon regions Please, contact your local IBA representative Radioactive concentrations 90 MBq/mL at the date and time of calibration Calibration 2 to 3 hours from the time of production Available quantities 90 to 900 MBq per vial at calibration time Expiry 8 hours from the date of production Volume per vial 1 to 10 mL Radiochemical purity ≥ 95% pH and composition 4.0-5.5 ; Fluorodopa ( 18 F), acetic acid, sodium acetate, ascorbic acid and water for injections Storage Store in the original lead shielding. After first withdrawal, store in refrigerator (2°C to 8°C). Indication Medicinal product for diagnostic use only. Indicated for use with positron emission tomography in neurology and oncology. Please, refer to the SPC.

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 12 | IBA Molecular | Availability of the products in the different countries according to the registration status. FARNA FDG 3000

Fluorine-18 T1/2 = 109.8 min Fludeoxyglucose ( 18 F) SOLUTION FOR INJECTION

Availability From Monday to Friday Ordering deadline Variable, depending on production sites Radioactive concentrations 3000 MBq/mL at calibration Calibration End of synthesis Available quantities From 1.0 to 10.0 mL per vial Expiry 14 hours from the end of synthesis Radiochemical purity ≥ 95% pH and composition 4.5-8.5 ; Fludeoxyglucose ( 18 F); sodium chloride, sodium dihydrogen phosphate dihydrate and water for injections, Ethanol. Storage No special conditions are required Indication Medicinal product for diagnostic use only. Fludeoxyglucose ( 18 F) is indicated for use with positron emission tomography. Please, refer to the SPC

FDG-IBA

Fluorine-18 T1/2 = 109.8 min Fludeoxyglucose ( 18 F) SOLUTION FOR INJECTION

Availability From Monday to Friday (Saturday in some instances) Ordering deadline Variable, depending on production sites Radioactive concentration 185 MBq/mL at time and date of calibration Calibration 5h, 5h30, 6h, 7h up to 9 hours from production Available quantities From 0.5 to 10.0 mL per vial (90 to 1850 MBq/mL) Expiry 12 hours from the time of production Radiochemical purity ≥ 95% pH and composition 4.5 - 8.5 ; Fludeoxyglucose ( 18 F), sodium chloride and water for injections Storage Store in the original package. After first withdrawal, store below 25°C and use within 12 hours without exceeding the expiry time. Indication Medicinal product for diagnostic use only. Fludeoxyglucose ( 18 F) is indicated for use with Positron Emission Tomography. Please, refer to the SPC

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. Availability of the products in the different countries according to the registration status. 13 | IBA Molecular | INTERNATIONAL CATALOGUE

FLUORSCAN 3000

Fluorine-18 T1/2 = 109.8 min Fludeoxyglucose ( 18 F) SOLUTION FOR INJECTION

Availability From Monday to Friday Ordering deadline Variable, depending on production sites Radioactive concentrations 3000 MBq/mL at time and date of calibration Calibration End of synthesis Available quantities From 1.0 to 10.0 mL per vial Expiry 14 hours from the end of synthesis Radiochemical purity ≥ 95% pH and composition 4.5-8.5 ; Fludeoxyglucose ( 18 F); sodium chloride, sodium dihydrogen phosphate dihydrate and water for injections, Ethanol. Storage No special conditions are required. Indication Medicinal product for diagnostic use only. Fludeoxyglucose ( 18 F) is indicated for use with positron emission tomography. Please, refer to the SPC

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 14 | IBA Molecular | Availability of the products in the different countries according to the registration status. SPECT & Therapy Radiopharmaceuticals

15 | IBA Molecular | INTERNATIONAL CATALOGUE

CAPSION ®

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) CAPSULE FOR THERAPY

Availability Every working day Ordering deadline Shipment Ordering deadline Monday Wednesday week before (before 11.00 am) Tuesday Thursday week before (before 11.00 am) Wednesday Thursday week before (before 11.00 am) Thursday Monday week before (before 11.00 am) Friday Tuesday (before 11.00 am) Available quantities From 50 MBq to 3700 MBq per capsule at calibration (100 mCi maxi per capsule) Calibration On request 1 - 4 days Expiry 21 days after the manufacturing date Specific activity at calibration у 185 GBq/mg of iodine at calibration Radiochemical purity Iodide : у 98% Radionuclidic purity 131 I у 99.9%; 130 I + 133 I + 135 I р 0.1% Storage Not above 25°C, in its original packaging. Indication • Treatment of Graves’ disease, toxic multinodular goitre or autonomous nodules • Treatment of papillary and follicular thyroid carcinoma including metastatic disease

ERMM-1

Erbium-169 T1/2 = 9.4 d ERBIUM ( 169 Er) CITRATE SUSPENSION FOR INJECTION (THERAPY)

Availability Tuesday Ordering deadline Friday before 11 a.m. Radioactive concentration 111 MBq/mL (3 mCi/mL) at calibration date Calibration Saturday 12 a.m. Available quantities From 37 to 1110 MBq Expiry 18 days from the manufacting date Specific activity 37 to 1110 MBq/mg (1 to 30 mCi/mg) at calibration date pH and composition 5.5 - 7.5 in sodium chloride solution Storage • Do not store above 25°C • After first withdrawal, store at 2-8°C and use within 8 hours. Indication Treatment of rheumatoid mono or oligo-arthritis involving one or few of the small joints of the hands and feet following failure of intra-articular corticosteroid therapy or when the latter is contra-indicated

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 16 | IBA Molecular | Availability of the products in the different countries according to the registration status. GA-67-MM-1

Gallium-67 T1/2 = 3.26 d GALLIUM ( 67 Ga) CITRATE SOLUTION FOR INJECTION

Availability Monday, Friday Ordering deadline Thursday week before (before 11.00 am CET) Radioactive concentration 74 MBq/mL (2 mCi/mL) Calibration Monday (next week) Friday (next week) 12 a.m. Available quantities From 37 to 1110 MBq Expiry 14 days after the manufacturing date Specific activity Carrier free Radiochemical purity у 95 % Radionuclidic purity у 99 %; 66 Ga р 0.2 % pH and composition 5 - 8 in sodium citrate solution Storage Not above 25°C 2 - 8°C after the first withdrawal and use within the working day. Indication • Non-specific tumor imaging and/or localising agent • Localisation of inflammatory lesions

I-123-S-2

Iodine-123 T1/2 = 13.2 h SODIUM IODIDE ( 123 I) SOLUTION FOR INJECTION

Availability Every working day except Friday and the day before a french banking holiday Ordering deadline One day before (before 11 a.m.) Radioactive concentration 18,5 MBq/mL Calibration Following day at 5 p.m. Available quantities 37 to 185 MBq Expiry 2 days after the manufacturing date Specific activity Carrier free Radiochemical purity у 95 % Radionuclidic purity у 99.7 % pH and composition 6.5 - 7.5 phosphate-thiosulfate buffer Storage 15-25°C Indication Functional and morphological study of the thyroid gland

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. Availability of the products in the different countries according to the registration status. 17 | IBA Molecular | INTERNATIONAL CATALOGUE

I-131-S-1

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) ORAL SOLUTION

Availability Tuesday / Wednesday Ordering deadline Thursday week before (before 4.00 pm CET) Radioactive concentration 1110 MBq/mL (30 mCi/mL) at calibration date Calibration Wednesday (following week) 12 a.m. Available quantities From 1 110 to 11 100 MBq Expiry 29 days after the manufacturing date Specific activity at calibration у 185 GBq/mg iodine Radiochemical purity Iodide : у 95 % Radionuclidic purity at calibration у 99.9 %; 133 I + 135 I + other alpha impurities р 0.1 % pH and composition 7 - 10 in sterile solution with carbonate-thiosulfate buffer Storage Not above 25°C Indication Diagnostic • Estimation of thyroid uptake and effective half life • Identification of thyroid remnant and metastases (after ablation) Therapy • Treatment of Graves’ disease, toxic multinodular goitre or autonomous nodules • Treatment of papillary and follicular thyroid carcinoma including metastatic disease

I-131-S-2

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) SOLUTION FOR INJECTION

Availability Thursday Ordering deadline Tuesday week before (before 11.00 am CET) Radioactive concentration 111 MBq/mL (3 mCi/mL) Calibration Friday (following week) 12 a.m. Available quantities From 74 to 1110 MBq Expiry 29 days after the manufacturing date Specific activity у 185 GBq/mg at calibration Radiochemical purity Iodide : у 95 % Radionuclidic purity at calibration у 99.9 %; 133 I + 135 I + other alpha impurities р 0.1 % pH and composition 6 - 8 in phosphate-thiosulfate buffer Storage Not above 25°C Indication Diagnostic • Estimation of thyroid uptake and effective half life • Management of thyroid carcinoma : identification of thyroid remnant and metastases (after ablation) Therapy • Treatment of Graves' disease, toxic multinodular goitre or autonomous nodules • Treatment of papillary and follicular thyroid carcinoma including metastatic disease

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 18 | IBA Molecular | Availability of the products in the different countries according to the registration status. MIBG-131-D

Iodine-131 T1/2 = 8.02 d IOBENGUANE ( 131 I) SOLUTION FOR INJECTION (DIAGNOSIS)

Availability Monday (one batch on 2 weeks) Ordering deadline Wednesday 11 a.m., the week before the shipment day Radioactive concentration 9.25 MBq/mL (0.25 mCi/mL) Calibration Tuesday (following week) 12 a.m. Precalibred quantities Monodose of 46.25 MBq (1.25 mCi) Expiry 19 days after the manufacturing date Specific activity 46.25 MBq/vial = 54.5 GBq of 131 I/g iobenguane at calibration Radiochemical purity у 94 % Radionuclidic purity at calibration 131 I у 99.9 % ; 133 I + 135 I + other impurities р 0.1 % pH and composition 4 - 6 in saline acetate buffer Storage At - 18°C Indication Calculation of a therapeutic iobenguane ( 131 I) dose from a prior tracer-dose (used for dosimetry in pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland)

MIBG-131-T

Iodine-131 T1/2 = 8.02 d IOBENGUANE ( 131 I) SOLUTION FOR INJECTION (THERAPY)

Availability Two first Tuesday of each month Ordering deadline Wednesday week before (before 11.00 am CET) Radioactive concentration 370 MBq/mL (10 mCi/mL) Calibration Thursday 12 a.m. Available quantities 1850 - 3700 and 5550 MBq (50 - 100 and 150 mCi) Maximum activity / vial 5550 MBq (150 mCi) Expiry 7 days after the manufacturing date Specific activity у 400 GBq of 131 I/g iobenguane at calibration Radiochemical purity у 92 % at expiry Radionuclidic purity 131 I у 99.9 % ; 133 I + 135 I + other impurities р 0.1% pH and composition 3.5 - 5.5 in saline acetate buffer Storage At - 18°C Indication Radiation therapy of tumour-tissue that is capable of retaining metaiodobenzylguanidine: pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. Availability of the products in the different countries according to the registration status. 19 | IBA Molecular | INTERNATIONAL CATALOGUE

NORCHOL-131

Iodine-131 T1/2 = 8.02 d (131 I) IODOMETHYLNORCHOLESTEROL SOLUTION FOR INJECTION

Availability Thursday Ordering deadline Friday, before 11 a.m. Radioactive concentration 7.5 - 15 MBq/mL (0.2 - 0.4 mCi/mL) at calibration Calibration Wednesday 12 a.m. Available quantities From 37 to 74 MBq per vial at calibration Expiry 14 days after the manufacturing date Specific activity 11 - 33 MBq/mg (0.3 - 0.9 mCi/mg) Radiochemical purity у 85 % Radionuclidic purity у 99.9 % pH 3.5 to 8.5 Storage At - 18°C Indications • Diagnostic evaluation of the functional state of adrenal cortical tissue • Differentiation between metastatic disease to the adrenals (“cold area”) and non-malignant adrenal enlargement in cancer patients • Detection of remnants of functioning tissue in hypercortisonism after adrenalectomy, or of ectopic endocrine tissue • Detection and follow-up of euadrenal tumours

QUADRAMET ®

Samarium-153 T1/2 = 46.3 h SAMARIUM ( 153 Sm) LEXIDRONAM PENTASODIUM SOLUTION FOR INJECTION (THERAPY)

Composition (153 Sm-EDTMP) : 1.3 GBq/mL (at calibration date) (Corresponding to 20 to 80 µg/mL of samarium) Total EDTMP (as EDTMP.H20) : 33 mg/mL Calcium-EDTMP sodium salt (as Ca) Total sodium (as Na) Water for injections Available activities 2 to 4 GBq per vial at calibration date Posology and method • 37 MBq per kg body weight of administration • Slow intravenous route through an established intravenous line over a period of one minute • Should not be diluted before use Availability and Calibration On Monday calibrated Thursday 12 a.m. Ordering deadline Friday week before (before 11.00 am CET) Expiry 4 days after the manufacturing date (1 day after the calibration date) Storage • Delivered frozen in dry ice, should be stored frozen at -10°C to -20°C in its original packaging • Use within 6 hours of thawing • After thawing, do not freeze again Therapeutic indications Relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium ( 99m Tc)-labelled biphosphonates on bone scan

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 20 | IBA Molecular | Availability of the products in the different countries according to the registration status. RE-186-MM-1

Rhenium-186 T1/2 = 3.77 d RHENIUM ( 186 Re) SULPHIDE SUSPENSION FOR INJECTION ( THERAPY)

Availability Tuesday Ordering deadline Friday before 11 a.m. Radioactive concentration 220 to 335 MBq/mL (6 to 9 mCi/mL) at calibration date Calibration Saturday 12 a.m. Available quantities From 37 to 3700 MBq Expiry 10 days after the manufacturing date Specific activity 2000 to 7400 MBq/mg (54 to 200 mCi/mg) Radiochemical purity у 95 % Radionuclidic purity 186 Re у 99 %; 184 Re + 188 Re р 1% pH and composition 3.5 - 5.5, colloidal suspension stabilised with gelatine Storage Not above 25°C Indication • Treatment of rheumatoid mono or oligo arthritis involving medium- sized joints (shoulders, elbows, wrists, ankles, hips) and particularly rheumatoid polyarthritis • Treatment of haemophilic or chronic arthropathy associated with articular chondrocalcinosis.

SERALB-125

Iodine-125 T1/2 = 59.9 d IODINATED ( 125 I) HUMAN ALBUMIN SOLUTION FOR INJECTION

Availability Thursday (once a month) Ordering deadline Monday, before 11 a.m. Radioactive concentration 185 kBq/mL (5 µCi/mL) at calibration date Calibration Saturday (2 weeks after) 12 a.m. Available quantities Per 4 vials of 320 kBq (8.6 µCi) Expiry 49 days after the manufacturing date Radiochemical purity у 80 % Radionuclidic purity у 99 % pH and composition 5 - 9 Storage At 2 to 8°C in its original packaging Indication • Determination of plasma volume and total blood volume • Examination of albumin turnover.

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. Availability of the products in the different countries according to the registration status. 21 | IBA Molecular | INTERNATIONAL CATALOGUE

TL-201-S-1

Thallium-201 T1/2 = 3.05 d THALLIUM ( 201 Tl) CHLORIDE SOLUTION FOR INJECTION

Availability and calibration On Monday calibrated Friday noon On Tuesday calibrated Sunday noon On Wednesday calibrated Tuesday noon On Thursday calibrated Wednesday noon On Friday calibrated Thursday noon Ordering deadline 1 day before the shipment day, before 11 a.m. Radioactive concentration 37 MBq/mL (1mCi/mL) Available quantities From 185 to 555 MBq Expiry 14 days after the manufacturing date Specific activity у 3.7 MBq/µg (0.1 mCi/µg) Radiochemical purity у 95 % Radionuclidic purity у 97 % Release Expiry 200 Tl < 0.25 % < 0.01 % 202 Tl < 0.50 % < 2.00 % 203 Pb < 0.10 % < 0.05 % pH and composition 4 - 7 in sterile isotonic solution Storage Between 15-25°C in its original packaging. 2 - 8°C after the first withdrawal and used within 24h. Indication • Myocardial scintigraphy in the evaluation of coronary perfusion and cellular viability. • Scintigraphy of the muscles. • Parathyroid scintigraphy. • Thallium avid tumour visualisation in different organs, especially for the brain tumours and thyroid tumours and metastases.

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. 22 | IBA Molecular | Availability of the products in the different countries according to the registration status. YMM-1

Yttrium-90 T1/2 = 2.67 d YTTRIUM ( 90 Y) CITRATE SUSPENSION FOR INJECTION (THERAPY)

Availability Tuesday Ordering deadline Friday before 11 a.m. Radioactive concentration 145 to 370 MBq/mL (1 to 10 mCi/mL) at calibration date Calibration Saturday 12 a.m. Available quantities From 37 to 3700 MBq Expiry 15 days after the manufacturing date Specific activity 59 to 300 MBq/mg Non filtrable fraction у 85% at release - у 80% at expiry of Yttrium-90 citrate colloidal suspension pH and composition 5.5 - 7.5 in sodium chloride solution Storage Not above 25°C Indication Therapeutic irradiation of synovial hypertrophy of knee joints mainly for mono- or oligo-articular arthritis of chronic inflammatory rheumatism particularly rheumatoid polyarthritis

YTRACIS ®

Yttrium-90 T1/2 = 2.67 d YTTRIUM ( 90 Y) CHLORIDE RADIOPHARMACEUTICAL PRECURSOR SOLUTION

Availability Tuesday Ordering deadline Thursday before 2 p.m. Radioactive concentration 1.85 GBq/mL Calibration Friday 12 a.m. CET Available quantities 0.925 to 3.700 GBq/vial Expiry 7 days after the manufacturing date Specific activity Carrier free Radiochemical purity у 97 % Acidity 0.035M-0.045M Storage Store in its original packaging Indication To be used only for in vitro radiolabelling of medicinal products which are subsequently administered by approved route.

IMPORTANT: Read package leaflet before using the radiopharmaceutical product. Availability of the products in the different countries according to the registration status. 23 | IBA Molecular | INTERNATIONAL CATALOGUE

24 | IBA Molecular | SPECT Cold kits (Kits for radiopharmaceutical preparation)

25 | IBA Molecular | INTERNATIONAL CATALOGUE

ANGIOCIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Sodium pyrophosphate decahydrate 20.12 mg Stannous chloride dihydrate Volume of 0.9% sodium chloride sterile solution to use for reconstitution 3 mL Storage 12 months at 2 to 8°C Stability of reconstituted product 6 h at 2 to 8°C Indications /Posology • Angiocardioscintigraphy • Organ perfusion and vascular abnormality imaging • Diagnosis and localisation of occult gastro-intestinal bleeding Activity injected for blood pool scintigraphy (740 - 925 MBq) Time between injection of Angiocis and 30 minutes before administration of pertechnetate 99m Tc pertechnetate 99m Tc Time between injection and examination Immediatly after injection of the tracer (pertechnetate 99m Tc) Availability From stock Number of radiolabelled preparations per kit 5

EDICIS ™ 2 mg

Kit for radiopharmaceutical preparation

Each vial 1 contains: Ethylene-dicysteine: 2 mg Disodium phosphate dihydrate (E339) D-mannitol (E421) Ascorbic acid (E300) Disodium edetate dihydrate

Each vial 2 contains: Reducing agent: Stannous chloride dihydrate (E512) Tartaric acid (E334) Ascorbic acid (E300)

Each vial 3 contains: Buffering agent: Potassium dihydrogen phosphate (E340) Ascorbic acid (E300) Volume of pertechnetate 99m Tc to use for reconstituton 2 mL Radiochemical purity у 95% Storage 1 year at 2-8°C Activity per vial 0,8 to 1,6 GBq Indications /Posology Dynamic scintigraphy in adults for: • Evaluation of nephropathies and uropathies especially for assessing relative kidney function, renal morphology, and renal perfusion. • Drainage of the upper urinary tract. The recommended activity for a patient of 70 kg average body weight is between 90 MBq and 120 MBq injected intravenously Stability of labelled product 8 hours not above 25°C Time between injection and examination The scintigraphic examination begins immediately after injection of the product. The total duration of the examination is approximately 30 minutes. Availability From stock Number of radiolabelled preparations 4

IMPORTANT: Read package leaflet before using the kit. 26 | IBA Molecular | Availability of the products in the different countries according to the registration status NANOCIS ®

Kit for radiopharmaceutical preparation

Each vial A contains Rhenium sulfide (as Re element 0.15 mg) 0.24 mg Gelatin Ascorbic acid Water for injections Concentrated hydrochloric acid Each vial B contains Sodium pyrophosphate decahydrate Stannous chloride dihydrate Sodium hydroxide Particle size 31.6 nm < 70% < 178 nm Volume of pertechnetate 99m Tc to add into vial A 1 to 2 mL Radiochemical purity у 95% Aspect of reconstituted product Dark brown colloidal solution Storage 6 months at 2 - 8°C Stability of labelled product 4 h at 2 - 8°C Activity per vial 370 to 5550 MBq Indications /Posology • Imaging and detection of sentinel lymph node : 5 to 200 MBq: activity and volume injected depending on the indication. • Lymphatic flow scintigraphy : 20 to 200 MBq in 0.2 to 0.3 mL / site Vol max/injection site: 0.5 mL • Gastro Oesophageal Reflux : 3.5 to 12 MBq Availability From stock Number of radiolabelled preparations per kit 5

OSTEOCIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Sodium oxidronate (HMDP) 3.0 mg Stannous chloride dihydrate Ascorbic acid Sodium chloride Under nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution 2 to 10 mL Radiochemical purity у 95 % Storage 12 months at 2 to 8°C Activity per vial 0.74 to 11.1 GBq Indications / Posology Bone scintigraphy 300 to 700 MBq / 50 or 70kg adult 500 MBq average activity Stability of labelled product 8h at 2 - 8ºC Time between injection and examination Not earlier than 2h after injection Availability From stock Number of radiolabelled preparations per kit 5

IMPORTANT: Read package leaflet before using the kit. Availability of the products in the different countries according to the registration status 27 | IBA Molecular | INTERNATIONAL CATALOGUE

PENTACIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Calcium trisodium pentetate (DTPA Ca Na 3) 9.10 mg Stannous chloride dihydrate Sodium chloride Under a nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution 5 mL Radiochemical purity у 95% Storage 12 months at 2 - 8°C Activity per vial 3.7 to 2000 MBq Indications / Posology 1) Intravenous use : - Renal glomerular filtration 1.8 to 3.7 MBq (plasma) - Renal glomerular filtration 37 to 370 MBq (scanning) - Brain scanning 185 to 740 MBq 2) Oral use : Study of gastro-oesophageal reflux and gastric emptying : 10 to 20 MBq Stability of labelled product 4h at 2 - 8°C with a maximum of 5 withdrawals per vial Time between administration and examination Optimal static renal imaging : 1 hour Renal and brain sequential scanning : immediately Brain static images : 1 hour to several hours Dynamic recording : first minutes up to 120 minutes for gastroduodenal transit. Availability From stock Number of radiolabelled preparations per kit 5

PHYTACIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Sodium phytate 20 mg Stannous chloride dihydrate Sodium hydroxide Under nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution 10 mL max. Radiochemical purity у 95% Storage 6 months at 2 - 8°C Stability of labelled product 6 h at 2 - 8°C Activity per vial 9250 MBq max. Indications /Posology Hepatic scintigraphy : 37 to 100 MBq Time between injection and examination 10 to 60 min Availability From stock Number of radiolabelled preparations per kit 5

IMPORTANT: Read package leaflet before using the kit. 28 | IBA Molecular | Availability of the products in the different countries according to the registration status PULMOCIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Human Albumin Macroaggregates (MAA) 2.0 mg Stannous chloride dihydrate Sodium chloride Non denaturated human albumin Under nitrogen atmosphere Particles number per vial 2 to 4 million Particle size Number of MAA у 150 ␮m : 0 Number of MAA у 100 ␮m : 0.2 % Volume of pertechnetate 99m Tc to use for reconstitution 2.5 - 10 mL Radiochemical purity* у 90 % Colour Whitish homogeneous suspension Storage 12 months at 2 - 8 °C Activity per vial 92.5 to 3700 MBq Indications Pulmonary perfusion scintigraphy Venoscintigraphy Posology 37 to 185 MBq Stability of labelled product 8 h at 2 - 8°C Time between injection and examination Immediately Availability from stock Number of radiolabelled preparations per kit 5

*Non filterable radioactivity

RENOCIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Dimercaptosuccinic acid (DMSA) 1.0 mg Stannous chloride dihydrate Inositol Ascorbic acid Sodium hydroxide (pH adjustment) Under nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution 1 to 6 mL Radiochemical purity у 95 % Storage 12 months at 2 to 8°C Stability of labelled product 8 h at 2 - 8°C Activity per vial Maximum 3.7 GBq Indications /Posology Static planar or tomographic renal imaging : - Morphological studies of renal cortex - Individual kidney function - Location of ectopic kidney 30 to 120 MBq Time between injection and examination Image acquisitions : 1 to 3 h Where there is renal impairment or obstruction, delayed views may be needed (6 to 24 hours respectively) Availability From stock Number of radiolabelled preparations per kit 5

IMPORTANT: Read package leaflet before using the kit. Availability of the products in the different countries according to the registration status 29 | IBA Molecular | INTERNATIONAL CATALOGUE

SCINTIMUN ® 1 mg

Kit for radiopharmaceutical preparation

Each vial 1 contains 5.02 mg dry substance : Besilesomab 1 mg Disodium hydrogen phosphate, anhydrous Sodium dihydrogen phosphate, anhydrous Under nitrogen atmosphere Sorbitol E420 Each vial 2 contains 2.82 mg dry substance : 1,1,3,3-propane tetraphosphonic acid, tetrasodium salt, dihydrate (PTP) 2.7 mg Tin (II) chloride dihydrate Sodium hydroxyde 1N (pH adjustment) Hydrochloric acid 1N (pH adjustment) Under nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution into vial 1 2 to 7 mL Radiochemical purity у 95 % Storage 2 years at 2 - 8°C, protected from light Stability of labelled product 3 h not above 25°C, protected from light Activity per vial 400 to 1800 MBq Indications /Posology In conjunction with other appropriate imaging modalities determination of the location of inflammation/infection peripheral bone in adults with suspected osteomyelitis (400-800 MBq). Should not be used for the diagnosis of diabetic foot infection Time between injection and examination 3 to 6h and late image 24h Availability From stock Number of radiolabelled preparations per kit 2

IMPORTANT: Read package leaflet before using the kit. 30 | IBA Molecular | Availability of the products in the different countries according to the registration status STAMICIS ®

Kit for radiopharmaceutical preparation

Each vial 2 contains Tetrakis (2-methoxy isobutyl isonitrile) 1.0 mg copper (I) tetrafluoroborate Stannous chloride dihydrate L-cysteine hydrochloride monohydrate Sodium Citrate Dihydrate Mannitol Volume of 99m Tc pertechnetate to use for reconstitution 1 to 3 mL Radiochemical purity > 94% Indications /Posology Adults The suggested activity range for intravenous use to a patient of average weight (70 kg) is: Myocardial perfusion scintigraphy: 400-900 MBq Assessment of global ventricular function: 600-800 MBq injected as a bolus. For diagnosis of ischaemic heart disease two injections (stress and rest) are required in order to differentiate transiently from persistently reduced myocardial uptake. The recommended activity range for diagnosis of ischaemic heart disease according to the European procedural guideline is: - Two-day protocol: 600–900 MBq/study - One-day protocol: 400–500 MBq for the first injection, three times more for the second injection. Not more than a total of 2000 MBq should be administered for a one-day protocol and 1800 MBq for a two-day-protocol. For a one day protocol, the two injections (stress and rest) should be done at least two hours apart but may be performed in either order. After the stress injection, exercise should be encouraged for an additional one minute (if possible). For diagnosis of myocardial infarction one injection at rest may be sufficient. The injection of activities greater than local DRLs (Diagnostic Reference Levels) should be justified. Scinti-mammography for the detection of suspected breast cancer: 750-1000 MBq injected as a bolus in the arm opposite to the lesion. Localisation of hyperfunctioning parathyroid tissue: 200–1000 MBq injected as a bolus (the activity used should in every case be as low as reasonably practical). The typical activity is 740 MBq. Children and adolescents For pediatric use, please refer to the full SPC. Time between injection and examination Myocardial perfusion scintigraphy If possible, patients should fast for at least four hours prior to the study. It is recommended that patients eat a light fatty meal or drink a glass or two of milk after each injection, prior to imaging. This will promote rapid hepatobiliary clearance of technetium (99m Tc) sestamibi resulting in less liver activity in the image. Imaging should begin approximately after 60 min after injection to allow for hepatobiliary clearance. Longer delay can be required for resting images and for stress with vasodilatators alone because of the risk of higher subdiaphragmatic 99m Tc activity. There is no evidence for significant changes in myocardial tracer concentration or redistribution, therefore imaging for up to 6 hours post injection is possible. Test may be done in a one day or two days protocol. Preferably tomographic imaging (SPECT) with or without ECG

IMPORTANT: Read package leaflet before using the kit. Availability of the products in the different countries according to the registration status 31 | IBA Molecular | INTERNATIONAL CATALOGUE

STAMICIS ® (continued)

gating should be performed according to current international guidelines. Breast imaging The product is administered in an arm vein contralateral to the breast with the suspected abnormality. If the disease is bilateral, the injection is ideally administered in a dorsal vein of the foot. Breast imaging is optimally initiated 5 to 10 minutes post injection with the patient in the prone position with breast freely pendant. A 10 minute lateral image of the breast suspected of containing cancer should be obtained with the camera face as close to the breast as practical. The patient should then be repositioned so that the contralateral breast is pendant and a lateral image of it should be obtained. An anterior supine image may then be obtained with the patient’s arms behind her head. Parathyroid imaging Acquisition depends on the protocol chosen. The most used studies are either the dual-phase and/or the subtraction techniques, which can be performed together. • Subtraction technique of the activity of the thyroid: In order to visualize the parathyroid, either pertechnetate( 99m Tc) or iodine ( 123 I) can be given first, followed by technetium ( 99m Tc) sestamibi, or technetium ( 99m Tc) sestamibi can be given first, followed by pertechnetate ( 99m Tc). When iodine ( 123 I) is used, 10 to 20 MBq of oral iodine ( 123 I) are administered. Four hours after the administration of 123 I, neck and thorax images are obtained. After iodine ( 123 I) image acquisition, 185 to 370 MBq of technetium ( 99m Tc) sestamibi are injected and images are acquired 10 minutes post injection in double acquisition with 2 peaks of gamma energy (140 keV for technetium ( 99m Tc) and 159 keV for iodine ( 123 I)). When pertechnetate ( 99m Tc) is used to visualize the parathyroid, 40-150 MBq of sodium pertechnetate( 99m Tc) are injected and neck and thorax images are acquired 30 minutes later. Then 185- 370 MBq of technetium ( 99m Tc) sestamibi are injected and a second acquisition of images is acquired 10 minutes later. • Dual-phase study: 350-1000 MBq of technetium ( 99m Tc) sestamibi are injected. Early (10 min. postinjection) and delayed (1.5-2.5 h postinjection) high- count images are obtained. In case of kidney failure, exposure to ionising radiation can be increased. This must be taken into account when calculating the activity to be administered. In general, activity selection for patients with a decreased hepatic function should be cautious, usually starting at the low end of the dosing range. Storage 1 year not above 25°C. Keep the vial in the outer carton, in order to protect from light. Stability of labelled product 10 h not above 25°C. Activity per vial 200 MBq to 11 GBq Availability From stock Number of radiolabelled preparations per kit 5

IMPORTANT: Read package leaflet before using the kit. 32 | IBA Molecular | Availability of the products in the different countries according to the registration status TECEOS ®

Kit for radiopharmaceutical preparation

Each vial contains : 3,3-diphospho - 1,2 -propanedicarboxylic acid, tetrasodium salt (DPD) 13.0 mg tin (II) - oxide N - (4 - aminobenzoyl) - L - glutamic acid, monosodium salt Volume of pertechnetate 99m Tc to use for reconstitution 2 to 10 mL Radiochemical purity у 95 % Storage 13 months, not above 25°C Stability of labelled product 8 h not above 25°C. Activity per vial 0.37 to 11.1 GBq Indications /Posology Bone scintigraphy 500 MBq (300 - 700 MBq) Time between injection and examination Late phase static scintigraphy should be performed not earlier than 2 hours Availability From stock Number of radiolabelled preparations per kit 5

VASCULOCIS ®

Kit for radiopharmaceutical preparation

Each vial contains : Human Serum Albumin (HSA) 10 mg Stannous chloride dihydrate Sodium chloride Under nitrogen atmosphere Volume of pertechnetate 99m Tc to use for reconstitution 1 to 8 mL Radiochemical purity у 95 % Storage 12 months at 2 to 8°C Activity per vial 92.5 to 2220 MBq Indications /Posology 1) Static blood pool imaging : 111 to 185 MBq 2) Angiography : 370 to 740 MBq 3) Circulation, blood flow studies : 18.5 to 185 MBq 4) Ventriculography : 185 to 925 MBq Stability of labelled product 8 h not above 25°C Time between injection and examination Shortly or immediately Availability From stock Number of radiolabelled preparations per kit 5

IMPORTANT: Read package leaflet before using the kit. Availability of the products in the different countries according to the registration status 33 | IBA Molecular | INTERNATIONAL CATALOGUE

ZEVALIN ®

Kit for radiopharmaceutical preparations for infusion

Vial 1: Ibritumomab tiuxetan 3 ml glass septum vial containing 2 ml ibritumomab tiuxetan (1.6 mg/ml) in 0.9% NaCl solution Vial 2: Sodium acetate 3 ml glass septum vial containing 2 ml 50 mM sodium acetate which is used to adjust the 90 Y-chloride solution to pH 4 Vial 3: Formulation buffer Glass septum vial containing 10 ml PBS (pH 7.2) with 7.5% human serum albumin and 1 mM DTPA Vial 4: Reaction vial: 10 ml empty glass septum vial Storage Components stored in refrigerator (2–8 ºC). Do not freeze ! Indications [90 Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction inpreviously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B- cell non-Hodgkin’s lymphoma (NHL). Stability After radiolabelling, an immediate use is recommended. Chemical and physical in-use stability has been demonstrated for 8 hours at 2°C - 8°C and protected from light. Number of radiolabeled preparations per kit 1

IMPORTANT: Read package leaflet before using the kit. 34 | IBA Molecular | Availability of the products in the different countries according to the registration status SPECT Generators

35 | IBA Molecular | INTERNATIONAL CATALOGUE

ELUMATIC ® III / TEKCIS ™ are automatic and highly protected generators which produce a sterile and pyrogen free 99m Tc solution, in the form of sodium pertechnetate (T = 6.02 h). This solution is eluted from an alumina chromatographic column on which fission 99 Mo is fixed (T = 66 h). The ELUMATIC ® III / TEKCIS ™ GENERATORS have an activity expressed in 99m Tc at the date indicated on the label. Elution solution : aqueous sterile and pyrogen free 0.9 % sodium chloride and 0.005% sodium nitrate solution.

ELUMATIC ® III

Technetium 99m Tc generator

Availability and Calibration on Monday calibrated Saturday 12 a.m. on Tuesday calibrated Saturday or Wednesday (following week) 12 a.m. on Wednesday calibrated Wednesday (following week) 12 a.m. on Thursday calibrated Wednesday 12 a.m. on Friday calibrated Wednesday or Saturday (following week) 12 a.m. Ordering deadline 5 days before the shipment day, before 11 a.m. Expiry 20 days from the date of manufacturing. Elution volume 5, 10 or 15 mL Radiochemical purity у 95 % Radionuclidic purity 99 Mo р 0.1 %, 131 I р 5.10 -3 %, 103 Ru р 5.10 -3 %, 89 Sr р 6.10 -5 %, 90 Sr р 6.10 -6 %, ␣ emitting impurities р 1.10 -7 %, other gamma-emitting impurities р 0,01 %. pH 4.0-8.0 Storage - Generator : 20 days between +15°C and +25°C - Sodium ( 99m Tc) pertechnetate solution : store at 2-8°C and use within 10 hours after elution. Precalibred quantities 2 - 4 - 6 - 8 - 10 - 12 - 16 - 20 GBq Indications 1. Reagent for labelling various kits to be used with 99m Tc 2. Administered intravenously the eluate might be used in: • Thyroid scintigraphy • Salivary gland scintigraphy • Localization of ectopic gastric mucosa • Cerebral scintigraphy 3. In conjunction with a reducing agent for labelling red blood cells for : • Cardiac and vascular scintigraphy • Diagnosis and localisation of occult gastrointestinal bleeding 4. Administered by instillation into the eye for: • Lacrymal duct scintigraphy

IMPORTANT: Read package leaflet before using the kit. 36 | IBA Molecular | Availability of the products in the different countries according to the registration status TEKCIS ™

2-50 GBq radionuclide generator

Availability and Calibration Every working days Calibration 5 and 8 days Ordering deadline 5 days before the shipment day, before 11 a.m. CET Expiry 21 days after manufacturing date Elution volume 5, 10 or 15 mL Radiochemical purity у 95 % Storage This medicinal product does not require any special storage conditions. Precalibrated activity 2-4-6-8-10-12-16-20-25-50 GBq Indications • Labelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such solution. • Thyroid scintigraphy: • Salivary gland scintigraphy • Location of ectopic gastric mucosa (Meckel's diverticulum). • Lacrimal duct scintigraphy.

IMPORTANT: Read package leaflet before using the kit. Availability of the products in the different countries according to the registration status 37 | IBA Molecular | INTERNATIONAL CATALOGUE

38 | IBA Molecular | SPECT Accessories

39 | IBA Molecular | INTERNATIONAL CATALOGUE

ELUMATIC ® III / TEKCIS ™ generators accessories

CONT - ELU TC - ELU - 5 - 10

Lead container for the protection of Kit containing 10 vials of 5 mL vacuum, sterile and pyrogen vacuum vials for the elution of the free, for the elution of the ELUMATIC ® III / TEKCIS ™ ELUMATIC ® III / TEKCIS ™ generators (with generators. a flat lead glass window).

TC - ELU - 10 - 10

CONT - ELU - SP Kit containing 10 vials of 10 mL vacuum, sterile and pyrogen free, for the elution of the ELUMATIC ® III / TEKCIS ™ Total vision lead glass and lead container generators. for the protection of vacuum vials for the elution of the ELUMATIC ® III / TEKCIS ™ generators. TC - ELU - 15 - 10

Kit containing 10 vials of 15 mL vacuum, sterile and pyrogen free, for the elution of the ELUMATIC ® III / TEKCIS ™ PROTEC - ELU generators.

Additional shielding for storage and elution of the ELUMATIC ® III / TEKCIS ™ generators (160 kg). Depending on national regulations.

ELUMATIC ® III

ELU-TIPS

Package of 10 units of sterilized needle caps are to protect the elution needle of ELUMATIC III (+ filter).

TEKCIS ™

PROT-STE-ELU STE-ELU

Plastic container for the protection of Kit containing 5 protective vials of sterile sterile vial (STE-ELU). elution needle for 99m Tc.

40 | IBA Molecular | Venticis ® II and accessories

VENTICIS ® II - RADIOAEROSOL DELIVERY SYSTEM

Venticis ® is an aerosol generator intended for - Study of pulmonary ventilation - Study of alveolar-capillary permeability using radiopharmaceutical products labelled with technetium 99m Tc. Medical device, class IIa, CE marked, in compliance with the Medical Devices Directive 93/42/EEC. 0459

1 - Nebulizer 2 - Air supply tubing 3 - External loader 4 - Reservoir bag 5 - Valves 6 - Mouthpiece 7 - Filter trap 8 - Lead shielded box

99mTc aérosol inhalé 99mTc aérosol exhalé Inhaled 99mTc aerosol Exhaled 99mTc aerosol

Availability : from stock, by 5 units

VENTIBOX - LEAD SHIELDED BOX FOR ONE VENTICIS ® II SYSTEM

Size closed box l. : 220 mm w. : 154 mm h. : 360 mm w. : 16 kg

41 | IBA Molecular | INTERNATIONAL CATALOGUE

CAPSION ® accessories

Tong Lead transportation pot for 131 Iodine capsule

Perforator Guide

EDICIS accessory

EDI-STRIPS Chromatographic paper Whatman 31 ET chr (10 per unit) for EDICIS QC

42 | IBA Molecular | SCINTIMUN ® accessory

HAMA-POCT Quick HAMA kit (5 tests per kit)

STAMICIS ® accessories

Tong Wet boiler

QC strips (according to SPC) Lead protection for Stamicis ® vials

43 | IBA Molecular | INTERNATIONAL CATALOGUE

44 | IBA Molecular | Radiochemical I-123-MPUP

45 | IBA Molecular | INTERNATIONAL CATALOGUE

I-123-MPUP Iodine-123 T1/2 = 13.2 h SODIUM IODIDE ( 123 I) SOLUTION FOR LABELLING

Availability Every working day except Thursday, Friday and the day before a day off Ordering deadline One day before (before 11 a.m.) Radioactive concentration 3700 MBq/mL (100 mCi/mL) Calibration Following day at 5 p.m. Precalibred quantities 92.5 - 148 - 185 - 259 - 296 MBq 2.5 - 4 - 5 - 7 - 8 mCi Expiry 2 days after the manufacturing date Specific activity Carrier free Radiochemical purity у 95 % Radionuclidic purity у 99.7 % pH and composition у 7 in sodium hydroxide 0.02 M Storage Not above 25°C Indication Labelling of radiopharmaceuticals API (Active Pharmaceutical Ingredients)

46 | IBA Molecular | Packaging PET SPECT

47 | IBA Molecular | INTERNATIONAL CATALOGUE

PET FDG-IBA

Vial Lead pot Box

48 | IBA Molecular | SPECT Radiopharmaceuticals

15 mL penicillin type vial Lead shields (according to nominal activities)

Metallic box (easy open system) Packaging

ELUMATIC ® III TEKCIS ™

Drum Plastic packaging

49 | IBA Molecular | INTERNATIONAL CATALOGUE

50 | IBA Molecular | Services

51 | IBA Molecular | INTERNATIONAL CATALOGUE

Imagem

Imagem is a web plateform on molecular imaging proposing a unique database on Molecular Imaging (scientific articles, news and events) updated daily by information specialists.

Molecular imaging review

Molecular Imaging Review consolidates the key information published in the Molecular Imaging world. It includes PET/SPECT scientific articles in the major clinical axis (books, abstracts, events, news/press).

Frequency: Monthly

52 | IBA Molecular | General Information

Commercial information ...... 56 Scientific and technical information .... 57 Units ...... 59 Definitions ...... 60 Nuclides index ...... 61 Radioactive decay table ...... 63 Locations and contacts ...... 67

53 | IBA Molecular | INTERNATIONAL CATALOGUE

Commercial information

PACKAGING

Radioactive products are delivered in packaging in For each radioactive nuclide, regulations lay down accordance with procedures complying with the : maximum quantity limits of radioactivity defined as : • RECOMMENDATIONS of the International Atomic • type A packaging : low and medium radioactivity, Energy Agency in Vienna (IAEA) (1990 revised edition) • type B packaging : high radioactivity. and with the ensuing regulations, codes and agreements. Packaging used for radiopharmaceutical products is type A non-returnable packaging ; it complies with the • International Air Transport Association (IATA) Regulations. regulatory tests for mechanical resistance and protection • International Rail Transport Regulations (RID). from radiation. • International Maritime Code (OMCI) It consists of a “crimped metal box” containing cylindrical • European Agreement on International Road Transport lead shielding, whose thickness varies from 5 to 35 mm, (ADR) and an absorbent sponge. The shielding is kept in position inside the box by a mould of expanded polystyrene. The • French regulations on transport of radioactive materials. box is fixed inside cardboard packaging. The weight of Determination of the type of packaging is settled by the the packaging varies from 0.5 to 10 kg. dangerous nature of the transported material : depending on its radiotoxicity, radioactivity and its tendency to spread.

ORDERING INFORMATION

1. HOW TO ORDER ? 2. WHEN TO ORDER ? Orders may be placed by mail, telefax or telephone to your Please, refer to our « PRODUCTION CALENDAR » and local contact (see list on the back of the catalogue). To remember that orders should arrive at the customer avoid errors and delay, each order should include the service at least two working days before production dates following information : of all items concerned. - ship to : CUSTOMER’S NAME + ADDRESS Production Calendars are available online at: - invoice : NAME + ADDRESS (if different) www.ibamolecular.eu - PURCHASE ORDER NUMBER - CATALOGUE CODE + NAME OF PRODUCT 3. WHERE TO ORDER ? - QUANTITY REQUIRED In countries where we have no local representative, orders - DELIVERY DATE REQUIRED should be sent to : - SPECIAL PACKAGING OR SHIPPING INSTRUCTIONS. CIS bio international If a written order is confirmation of an order already B.P. 32 placed by telephone, this must be clearly indicated. 91192 Gif-sur-Yvette Cedex - FRANCE Duplicate shipment resulting from improperly confirmed Telefax : 33 1 69 85 75 21 or 33 1 69 85 72 89 formal order may not be returned for credit and both Enquiries should be sent to : invoices are integrally payable. CIS bio international Standing orders : B.P. 32 We welcome standing orders. They can be modified or 91192 Gif-sur-Yvette Cedex - FRANCE cancelled at any time, with at least one week’s notice.

54 | IBA Molecular | Scientific and technical information

QUALITY CONTROL

1. DEFINITIONS RADIOCHEMICAL PREPARATION RADIOPHARMACEUTICAL PREPARATION Products are generally presented in vials (penicillin type) (Directive 2004/27/EC amending Directive 2001/83/EC) of 2, 15 and 30 mL. Some of them are packaged in sealed ampoules. Radiopharmaceutical Any medicinal product which, when ready for use, contains Each package has one or two labels showing : the nature one or more radionuclides (radioactive isotopes) included of the product, the radioactive concentration at a given for a medicinal purpose. date, the volume and the lot number. Radionuclide generator A red symbol indicates the radioactive character of the Any system incorporating a fixed parent radionuclide product. from which is produced a daughter radionuclide which is 3. QUALITY CONTROL to be obtained by elution or by any other method and RADIOPHARMACEUTICAL PREPARATION used in a radiopharmaceutical. The manufacturing and distribution of radiopharmaceutical Kit preparations (1) must respond to official standards, or in Any preparation to be reconstituted or combined with default, to protocols established in agreement with the radionuclides in the final radiopharmaceutical, usually competent authorities. The standards, which are rendered prior to its administration. obligatory, are published in the pharmacopoeia (French, European, British pharmacopoeia, Pharmacopoeia of Radionuclide precursor the USA, etc.) Any other radionuclide produced for the radiolabelling (1) Acceptance put in concrete form by the the opening authorization of of another substance prior to administration. pharmaceutical branch CIS bio international. RADIOCHEMICAL PREPARATION : According to these documents, the establishment of a The designation radiochemical preparation refers to a quality control of the radiopharmaceutical preparations chemical product including one or more radiochemical seems to be relatively easy. In fact, if the general methods preparations. of manufacturing, distribution and control are effectively Must not be injected in human. described, all the radiopharmaceutical preparations are not included in monographs. 2. PRESENTATION RADIOPHARMACEUTICAL PREPARATION Moreover, as the various pharmacopoeia do not always Products are generally presented in vials (penicillin type) prescribe the same methods or the same standards, it is of 15 mL. necessary to render them compatible. All these facts explain the difficulty to imagine a control system which Some products appear in takes into consideration the whole international statutory • gelatin capsules restraints. • unidose plastic syringes, ready to use The quality control of the radiopharmaceutical • generators : chromatography columns allowing the preparation is effected at three levels : elution of short half-life radionuclides. RAW MATERIAL CONTROL Each package has a label showing the name of the All the raw materials entering the manufacturing of the product, the radioactive concentration, the specific radiopharmaceutical products are stored and analysed radioactivity at a given date, the volume, the lot number, before use following the rules of Quality Assurance. the expiry date and the conditions of storage. It contains The delivery system used allows immediate cross- also a package leaflet to read before using the product. checking, in case of anomaly both in production and in the finished product.

55 | IBA Molecular | INTERNATIONAL CATALOGUE

Scientific and technical information (continued)

QUALITY CONTROL

CONTROL OF THE MANUFACTURING RADIOCHEMICAL PREPARATION PROCESSES The radiochemical preparations are submitted to certain The manufacturing of radiopharmaceutical preparations controls at various levels of their production. imperatively requires the respect of Good Manufacturing There are 2 types of control : Practices describing the premises, the qualification of the manufacturing and control employees, and the • Radiometrological controls allowing the adjustment of the materials used to the considered identification of the radionuclides (in particular with g operations. spectrometry), the measuring of radioactivity which ensures the radioactive concentration. The verification of the respect of these rules is effected by the Quality Assurance which uses two inner • Physical and chemical controls allowing the characteristics : the impartiality towards the producer determination of the chemical purity of the radioactive and the availability of a suitable analytic procedure. solutions delivered. Radiochemical preparations must not be administered CONTROL OF THE FINISHED PRODUCTS to human. Systematic control of the raw materials and respect of the 4. STORAGE manufacturing procedures assure a quality guarantee The decomposition of the radiopharmaceutical which must be confirmed by the control of the finished preparations under the influence of their own radiation is product. a general phenomenon : in some cases it may shorten the There are 3 types of controls of the finished products : duration of use. • Radiometrological controls allowing the It is recommended identification of the radionuclides (in particular with g • to maintain the products, as soon as they arrive, at a spectrometry), the measuring of radioactivity which temperature suitable with their physical properties (the ensures the radioactive concentration and the specific particular conditions of storage are notified on the label). radioactivity. • to use them as rapidly as possible, the expiry date • Physical and chemical controls : is mentioned on each radiopharmaceutical preparation. The dosage of the active ingredients, the analysis of the radionuclidic and of the radiochemical purity, the measuring of the pH and the osmotic pressure demand various methods such as potentiometry, chromatography, electrophoresis, etc. • Biological controls : The injectable aqueous or colloidal solutions are, according to the monographs of the various Pharmacopoeia, submitted to controls of sterility, absence of abnormal toxicity, submitted to controls of sterility, bacterial endotoxin concentration and absence of abnormal toxicity. Besides, the quantitative analysis of the biodistribution of some radiopharmaceutical preparations is performed in animals.

56 | IBA Molecular | Units

Each radionuclide is characterized : Rem in Sievert : - by an unvarying period expressed in time unit 1 Millirem (mrem) = 10 Microsievert (µSv) - by the nature and the energy of the radiation(s) 1 Rem = 10 Millisievert (mSv) This energy is expressed in electronvolts (eV), 1 Rem = 1 Centisievert (cSv) kiloelectronvolts (keV), megaelectronvolts (MeV). Sievert in Rem : The radioactivity (activity) of a preparation is defined by the amount of desintegrations or nuclear transformations 1 Microsievert (µSv) = 0.1 Millirem (mrem) occuring in this preparation per unit of time. 1 Millisievert (mSv) = 100 Millirem (mrem) The quantities of radioactivity in the International System 1 Centisievert (cSv) = 1 Rem (IS) are expressed in becquerel (Bq), corresponding to 1 Sievert (Sv) = 100 Rem one nuclear transformation per second (dps = disintegration per second). The quantities of radioactivity may also be expressed in CONVERSION TABLE FROM BECQUERELS curie (Ci), the curie corresponding to 3.7 x 1010 INTO CURIES disintegrations per second, in millicurie, microcurie, or in nanocurie. kBq µCi MBq µCi The following factors make the conversion easier between MBq mCi GBq mCi the 2 unit systems : GBq Ci TBq Ci

Becquerel in Curie: 1 Bq = 27.027 pCi = 1 dps 3.7 0.1 1.11 30 1 Becquerel (Bq) = 27.027 Picocurie (pCi) 7.4 0.2 1.48 40 9.25 0.25 1.85 50 1 Kilobecquerel (kBq) = 27.027 Nanocurie (nCi) 1 Megabecquerel (MBq) = 27.027 Microcurie (µCi) 11.1 0.3 2.22 60 1 Gigabecquerel (GBq) = 27.027 Millicurie (mCi) 14.8 0.4 2.59 70 1 Terabecquerel (TBq) = 27.027 Curie (Ci) 18.5 0.5 2.96 80

Curie in Becquerel: 1 Ci = 3.7 x 1010 Bq 37 1 3.33 90 74 2 3.7 100 1 Nanocurie (nCi) = 37 Becquerel (Bq) 92.5 2.5 4.62 125 1 Microcurie (µCi) = 37 Kilobecquerel (kBq) 1 Millicurie (mCi) = 37 Megabecquerel (MBq) 111 3 5.55 150 1 Curie (Ci) = 37 Gigabecquerel (GBq) 148 4 7.4 200 185 5 9.25 250 1 Decacurie (daCi) = 0.37 Terabecquerel (TBq)

Rad in Gray: 1 Rad/mCi = 0.27 mGy/MBq 222 6 11.1 300 259 7 14.8 400 1 Millirad (mrad) = 10 Microgray (µGy) 296 8 18.5 500 1 Rad = 10 Milligray (mGy) 1 Rad = 1 Centigray (cGy) 333 9 22.2 600 370 10 25.9 700 Gray in Rad: 444 12 27.75 750 1 Microgray (µGy) = 0.1 Millirad (mrad) 1 Milligray (mGy) = 100 Millirad (mrad) 29.6 800 1 Centigray (cGy) = 1 Rad 33.3 900 37 1000 1 Gray (Gy) = 100 Rad

57 | IBA Molecular | INTERNATIONAL CATALOGUE

Definitions (*)

RADIONUCLIDIC PURITY ISOTOPIC CARRIER The ratio, expressed as a percentage, of the radioactivity A stable isotope of the element concerned either present of the radionuclide concerned to the total radioactivity of or added to the radioactive preparation in the same the radiopharmaceutical preparation. The relevant chemical form as that in which the radionuclide is present. radionuclidic impurities are listed with their limits in the individual monographs. SPECIFIC RADIOACTIVITY The radioactivity of a radionuclide per unit mass of the RADIOCHEMICAL PURITY element or of the chemical form concerned. The ratio, expressed as a percentage, of the radioactivity of the radionuclide concerned which is present in the RADIOACTIVE CONCENTRATION radiopharmaceutical preparation in the stated chemical The radioactivity of a radionuclide per unit volume. form, to the total radioactivity of that radionuclide present in the radiopharmaceutical preparation. The relevant radiochemical impurities are listed with their limits in the individual monographs.

CHEMICAL PURITY In monographs on radiopharmaceutical preparations chemical purity is controlled by specifying limits on chemical impurities.

(*) Refer to the European Pharmacopoeia, current edition, Monograph “Radiopharmaceutical preparations”.

58 | IBA Molecular | Nuclides index

Energies of main radiations emitted by the radionuclides used as radiopharmaceuticals.

Decay Emitted Energy Radionuclides Half life % Intensity Modes Radiations (Rev) ERBIUM-169 169 Er 9.3 d ␤- e- 373 max 42 351 max 58

- e C 6-7 33.4 8 8.4 ␥ 8.4 0.2 FLUORINE-18 18 F 1.83 h ␤+ e+ 633 max 96.6 (average 250) EC 3.1 ␥␥annihilation 511 96.9 GALLIUM-67 67 Ga 3.25 d EC 100% ␥ 912 3.1 932 35.4 185 22 209 2.4 300 16.5 393 4.5 IODINE-123 123 I 13.2 h EC 100% e- 127 13.6 154 1.77 158 0.43 22-32 12.4 2.3-4.8 98 ␥ 159 83.3 529 1.4

XK 27 70 31 16

XL 3.3-4.9 7.8 IODINE-125 125 I 59.9 d EC 100% ␥ 34.8 6.7 e- 22-31 20.8 34.4 2.4

Xk 27-32 139 4-5 13 IODINE-131 131 I 8.02 d ␤- e- 248 max 2.1 334 max 7.3 606 max 89.5 e- 46 3.5 ␥ 80 2.6 284 6 364 81.3 637 7.2 722 1

59 | IBA Molecular | INTERNATIONAL CATALOGUE

Nuclides index (continued)

Decay Emitted Energy Radionuclides Half life % Intensity Modes Radiations (Rev) RHENIUM-186 186 Re 3.77 d ␤- e- 1076 max 71 939 max 7.3 308 max 7.3 EC 7.6 ␥ 123 0.6 137 9.5 e- 63 4.1 e- 124-126 6 e- 5-13 12

XK 58-74 10.2

XL 7-13 5.2 SAMARIUM-153 153 Sm 46.3 h ␤- e- 640 max 30 710 max 50 810 max 20

- e C 21 24 55 41 95 6 ␥ 41 49 47 12 103 29 TECHNETIUM-99m 99m Tc 6.02 h ␥␥ 140 89.3 IC e- 119 8.7 121-142 2.14 2 99.1 15-18 2

XK 18-21 7.2 THALLIUM-201 201 TI 3.05 d EC 100% e- 27-31 2.7 52 7.4 84 15 ␥ 135 2.6 167 9.8

XK 69-83 95 YTTRIUM-90 90 Y 2.67 d ␤- e- 2284 max 99.98% average 939 average 523 0.02 average 188

Radiations used for a medical purpose EC : electron capture IC : internal conversion electrons

60 | IBA Molecular | Radioactive decay table

Tc - 99m I - 123 Sm - 153 Y - 90 Mo - 99 Hours Days T1/2 = 6.02 h T1/2 = 13.2 h T1/2 = 46.3 h T1/2 = 64.1 h T1/2 = 66.2 h -168 -7 6.149 5.805 -156 5.401 5.119 -144 -6 4.744 4.515 -132 4.167 3.982 -120 -5 3.660 3.512 -102 3.012 2.909 -96 -4 4.209 2.823 2.732 -84 3.517 2.480 2.409 -72 -3 2.938 2.178 2.125 -60 2.455 1.913 1.874 -48 -2 2.052 1.680 1.653 -36 1.714 1.476 1.458 -24 -1 1.432 1.296 1.286 -12 3.999 1.877 1.197 1.139 1.134 -8 2.519 1.521 1.127 1.090 1.087 -4 1.587 1.233 1.062 1.044 1.043 -3 1.414 1.170 1.046 1.033 1.032 -2 1.260 1.111 1.030 1.022 1.021 -1 1.122 1.054 1.015 1.011 1.011 Calibration 11111 1 0.891 0.949 0.985 0.989 0.990 2 0.794 0.900 0.971 0.979 0.979 3 0.707 0.854 0.956 0.968 0.969 4 0.630 0.811 0.942 0.958 0.959 5 0.561 0.769 0.928 0.947 0.949 6 0.500 0.730 0.914 0.937 0.939 7 0.446 0.693 0.901 0.927 0.929 8 0.397 0.657 0.887 0.917 0.920 9 0.354 0.624 0.874 0.907 0.910 10 0.315 0.592 0.861 0.898 0.901 12 0.250 0.533 0.836 0.878 0.882 14 0.480 0.811 0.860 0.864 16 0.432 0.787 0.841 0.846 20 0.350 0.741 0.806 0.811 24 1 0.284 0.698 0.771 0.778 36 0.151 0.583 0.678 0.686 48 2 0.081 0.487 0.595 0.605 60 0.043 0.407 0.523 0.534 72 3 0.340 0.459 0.471 84 0.403 0.415 96 4 0.354 0.366 108 0.311 0.323 120 5 0.273 0.285 144 6 0.211 0.221 168 7 0.163 0.172

61 | IBA Molecular | INTERNATIONAL CATALOGUE

Radioactive decay table (continued)

Hours Days Tl - 201 Ga - 67 Re - 186 T1/2 = 3.05 d T1/2 = 3.26 d T1/2 = 3.77 d -168 -7 -156 4.380 3.983 3.303 -144 -6 3.909 3.582 3.013 -132 3.489 3.220 2.748 -120 -5 3.114 2.895 2.507 -102 2.779 2.603 2.248 -96 -4 2.481 2.340 2.086 -84 2.214 2.104 1.903 -72 -3 1.977 1.892 1.736 -60 1.764 1.702 1.583 -48 -2 1.575 1.530 1.444 -36 1.406 1.376 1.317 -24 -1 1.255 1.237 1.202 -12 1.120 1.112 1.096 -8 -4 -3 -2 -1 Calibration 111 1 2 3 4 5 6 7 8 9 10 12 0.893 0.899 0.912 14 16 20 24 1 0.797 0.808 0.832 36 0.712 0.727 0.759 48 2 0.635 0.654 0.692 60 0.566 0.588 0.632 72 3 0.506 0.528 0.576 84 0.452 0.475 0.526 96 4 0.403 0.427 0.479 108 0.360 0.384 0.437 120 5 0.321 0.345 0.399 144 6 0.256 0.279 0.332 168 7 0.204 0.226 0.276 192 8 0.162 0.182 0.230

62 | IBA Molecular | Radioactive decay table (continued)

I - 131 Er - 169 I - 125 Hours Days T1/2 = 8.02 d T1/2 = 9.40 d T1/2 = 59.9 d -180 -7.5 2.373 -168 -7 1.831 1.084 -156 -6.5 1.371 1.615 -144 -6 1.679 1.556 -132 -5.5 1.608 1.500 -120 -5 1.540 1.446 1.060 -108 -4.5 1.475 1.393 -96 -4 1.413 1.343 -84 -3.5 1.353 1.294 -72 -3 1.296 1.248 1.035 -60 -2.5 1.241 1.202 -48 -2 1.189 1.159 -36 -1.5 1.138 1.117 -24 -1 1.090 1.077 1.012 -12 -0.5 1.044 1.038 Calibration 111 12 0.5 0.958 0.964 24 1 0.917 0.929 0.988 36 1.5 0.878 0.895 48 2 0.841 0.863 60 2.5 0.806 0.832 72 3 0.772 0.802 0.966 84 3.5 0.739 0.773 96 4 0.708 0.745 108 4.5 0.678 0.718 120 5 0.649 0.692 0.944 132 5.5 0.622 0.667 144 6 0.595 0.643 156 6.5 0.570 0.619 180 7 0.546 0.597 0.922 204 8 0.501 0.554 228 9 0.460 0.515 0.901 252 10 0.421 0.478 0.891 276 11 0.387 0.444 300 12 0.355 0.413 0.870 324 14 0.298 0.356 348 15 0.274 0.331 0.841 20 0.178 0.229 0.793 25 0.158 0.749 30 0.707 40 0.630 45 0.594 50 0.561 55 0.529 60 0.499

63 | IBA Molecular | INTERNATIONAL CATALOGUE

64 | IBA Molecular | Locations and contacts

IBA Molecular Europe IBA Molecular Rest of the world

Europe Head office South East Asia Mail address: IBA Molecular India Pvt, Ltd IBA Molecular D-131, Sector 63 CIS bio international Noida - 201301 BP 32 Uttar Pradesh 91192 Gif-sur-Yvette Cedex, India France P + 91 120 4335017 + 33 1 69 85 73 22 [email protected] Visitor address: IBA Molecular CEA Center - RN 306 North Asia - Japan - Australia and New Zealand 91400 Saclay, France n°6, Xing Guang Er Jie Beijing OPTO-Mechatronics Industrial Park (OIP) Tongzhou District, Beijing 101111 Europe Subsidiaries China France and Benelux offices P + 86 10 8080 9187 IBA Molecular France [email protected] CIS bio international BP 32 91192 Gif-sur-Yvette Cedex, South America France 55 Merrick Way, #602, P +33 1 69 85 73 35 Coral Gables FL 33134, USA [email protected] P + 1 305 962 0555 [email protected] Spain offices IBA Molecular Spain, SA Middle East, Africa, Turkey Avda. Dr. Severo Ochoa, 29 Manara, Concord tower, 6th floor 28100 Alcobendas (Madrid) Media Ciity , Dubai P + 34 914 905 648 UAE [email protected] P + 971 55 484 4268 [email protected] Germany IBA Molecular Germany Europe Cis bio GmbH IBA Molecular Alt- Moabit 91 d BP 32 - 91192 Gif sur Yvette 10559 Berlin, Germany France P + 49 30 8009 305 0 P +33 1 69 85 73 64 [email protected] [email protected] www.ibamolecular.de Pharmacovigilance Italy offices P +33 1 69 85 76 76 IBA Molecular Italy srl [email protected] CIS bio SpA Via Piccini, 2 20131 Milano Materiovigilance P + 39 02362632 P + 33 1 69 85 70 70 [email protected] Fax + 33 1 69 85 70 52 [email protected] IBA Molecular US Head office IBA Northen America 21 000 Atlantic Blvd, Ste 730 Dulles, VA 20166, USA [email protected] P +1 703 787 7900 www.ibamolecular.eu

65 | IBA Molecular | INTERNATIONAL CATALOGUE

66 | IBA Molecular | 67 | IBA Molecular | PRODUCT CATALOGUE 3 0 0 - 4 1 - D - Z - I - 5 1 0 2 h c r a M - E C I V R E S E

U CIS bio international Q I H P

A Member of IBA Molecular group of companies R G

A B.P. 32 - 91192 Gif-sur-Yvette Cedex T L E D

- France E C

N Tel : +33 1 69 85 75 70 A R F n i Fax : +33 1 69 85 72 09 d e t n i r P

www.ibamolecular.eu